Enzalutamide: A novel antiandrogen for patients with castrate-resistant prostate cancer

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1335-1339

  Hoffman Censits, Jean ^a   Kelly, Wm Kevin ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ASTELLAS; BICALUTAMIDE; CABAZITAXEL; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; LEUPRORELIN; MEDIVATION; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TESTOSTERONE; UNCLASSIFIED DRUG; ZYTIGIA;

ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BACKACHE; BONE METASTASIS; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL NUCLEUS; DIARRHEA; DNA TRANSCRIPTION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HEADACHE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; MUSCULOSKELETAL PAIN; NEUROPATHY; NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SIDE EFFECT; SOFT TISSUE; TISSUE REACTION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; DISEASE-FREE SURVIVAL; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; DRUG TOXICITY; HUMANS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84875150133     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2910     Document Type: Review

References (18)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5.
3. Knudsen KE, Penning TM. Partners in crime: Deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010;21:315-24.
4. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267-73.
5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
6. Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, LaPensee EW, Dhanasekaran S, et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009;69:4434-42.
7. Scher HI, Beer TM, Higano CS, Anand A, Taplin M, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
8. Higano CS, Beer TM, Taplin M, Efstathiou E, Anand A, Hirmand M, et al. Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study. ASCO Meeting Abstracts 2011;29:134.
9. Scher HI, Fizazi K, Saad F, Taplin M, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
10. Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res 2011;17:880-7.
11. Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011;71: 480-8.
12. Scher HI, Fiazi K, Saad F, Chi K, Taplin M, Sternberg CN, et al. Association of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 AFFIRM study of enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI). Ann Oncol 2012;23: xi297.
13. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376: 1147-54.
14. Ryan CJ, Smith MR, De Bono JS, Molina A, Logothetis C, De Souza PL, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). ASCO Meeting Abstracts 2012;30:LBA4518.
15. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.
16. Efstathiou E, Titus MA, Tsavachidou D, Hoang A, Karlou M, Wen S, et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report. ASCO Meeting Abstracts 2011;29:4501.
17. Parker C, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Demkow T, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. ASCO Meeting Abstracts 2012;30:8.
18. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.